NEW YORK (GenomeWeb News) – Transgenomic today announced it has received confirmation of Medicare coverage for its clopidogrel response test.

National Government Services, the Medicare fiscal intermediary for Connecticut, has confirmed coverage for Transgenomic's Clopidogrel Genetic Absorption Activation Panel, or C-GAAP, providing 48 million Americans currently on Medicare access to the test, formerly called PGxPredict: Clopidogrel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.